COMMON STOCK PURCHASE WARRANT, AS AMENDED MAY 10, 2023 ENSYSCE BIOSCIENCES, INC.Ensysce Biosciences, Inc. • May 15th, 2023 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT, AS AMENDED MAY 10, 2023 (the “Warrant”) certifies that, for value received, xxxxxxxx or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [________ __], 202x (the “Termination Date”) but not thereafter, to subscribe for and purchase from Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), up to xxxxx shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant reflects a revised Exercise Price in Section 2(b) agreed to by the Holder and it and the number of Warrant Shares have been adjusted for reverse stock splits effected by the Company on October 28, 2022, an
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 15th, 2023 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 10, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
